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Obesity results from alterations in the body’s regulation of energy intake, expenditure, and
storage. Animal and human data demonstrate that phylogenic changes occur in the micro-
biota composition in obese individuals. Furthermore, evidence from animalmodels suggest
that the alterations of the gut microbiota with obesity results in increased energy extraction
and lipid deposition, altered release of entero-hormones, increased intestinal permeabil-
ity and metabolic endotoxemia. Treatment with pre- and probiotics may reverse many of
metabolic effects linked with the altered microbiota in obese patients. The gut microbiota
is, therefore, a potential nutritional and pharmacological target for the management of
obesity and obesity-related disorders.
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Mammals, including humans, have, throughout their evolution,
been associated with complex microbial communities, which
inhabit the surfaces and alimentary tract of their host and which
outnumber the human somatic cells by a factor of 10. The human
intestinal microbiota is estimated to be composed of 1013 to 1014
microorganisms whose collective genome, the microbiome, con-
tains at least 100-fold more genes than the complete human
genome (Eckburg et al., 2005; Gill et al., 2006). The gut of a
neonate is sterile. However, at birth, the gut is immediately colo-
nized by maternal and environmental bacteria and the complexity
of the resulting gut microbiota increases until weaning to solid
foods. Although incompletely understood the gut microbiota
is implicated in a variety of host functions involving intestinal
development and function, including epithelial turnover, immune
modulation, gastrointestinal motility, and drug metabolism. The
gut microbiota also has important metabolic functions, breaking
down dietary toxins and carcinogens, synthesizing micronutri-
ents, fermenting indigestible food substances, assisting in the
absorption of certain electrolytes and trace minerals, and affect-
ing the growth and differentiation of enterocytes and colonocytes
through the production of short-chain fatty acids (SCFA; Mac-
farlane and Macfarlane, 1997; Zoetendal et al., 2001; Ouwehand
et al., 2002; Stappenbeck et al., 2002). Finally, the normal gut
microbiota helps prevent luminal colonization by pathogenic bac-
teria, such as Escherichia coli, Clostridia, Salmonella, and Shigella
species.
The composition of the adult intestinal microbiota has been
intensively studied, by means of culture-based methodologies
and, more recently, through culture independent technologies
based on the ampliﬁcation and direct sequencing of small sub-
unit ribosomal DNA sequences. Among the novel investigative
methods that are used to study the microbial ecology of com-
plex bacterial communities, the so-called metagenomics approach
is considered to represent the method that produces results of
“gold standard” quality (Eckburg et al., 2005; Gill et al., 2006).
Metagenomics is the study of microbial communities through
sequence-based, compositional and/or functional analyses of all
the combined microbial genomes contained within an environ-
mental sample. With respect to its application to human intestinal
microbiota, metagenomic studies of mucosal as well as fecal sam-
ples revealed the presence of representatives of the phylogenetic
groups Firmicutes, Bacteroidetes, Proteobacteria, Fusobacteria,
Verrucomicrobia, and Actinobacteria (Eckburg et al., 2005; Gill
et al., 2006; see Table 1). With a relative abundance of 25 and
65%, respectively, the two dominant phyla Bacteroidetes and Fir-
micutes represent together up to 90% of the total microbiota,
whereas Actinobacteria, Proteobacteria, and Fusobacteria are the
subdominant phyla with a relative abundance of about 5, 8, and
1%, respectively (Candela et al., 2010). At least 1800 genera and
16,000 phylotypes at the species level have been so far identiﬁed,
and an even greater diversity at the species level has been predicted.
The bacterial phyla are unevenly distributed along the length of
the gastrointestinal tract. Metagenomic analyses of jejunum sam-
ples reveal a distinctive community composition which includes
an abundance of bacteria belonging to the Streptococcus genus,
whereas Bacteroidetes and Firmicutes genera are the predominant
microbial groups identiﬁed in the distal ileum, ascending colon
and rectum.
The composition of ﬂora differs between individuals, with each
person having unique strains that generally remain constant over
time. Genetics, diet, immune status, infections, gastrointestinal
disorders as well as antibiotics and other drugs interact to deter-
mine an individual’s unique microbiome. The effect of genotype
on the composition of the human microbiota was demonstrated
in a study involving monozygotic twins (Zoetendal et al., 2001).
According to this report, there were greater similarities between
the gut microbiota of monozygotic twins than between monozy-
gotic twins and their unrelated marital partners. The importance
of the initial colonizing microbial community on the eventual
microbial composition of the gut is evident from animal stud-
ies. The composition of the mouse gut microbiota is signiﬁcantly
affected by maternal transmission (Ley et al., 2005). Diet is also
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a pivotal variable in inﬂuencing the composition of the intestinal
microbiota. Studies on chemically well-deﬁned diet components
have proven a clear correlation between diet and the presence
of speciﬁc bacterial groups. It has been shown that a diet rich
in inulin and related ﬁbers promote an increase in biﬁdobacte-
ria, whereas the intake of dietary sulfate favors several genera of
sulfate-reducing bacteria over methanogenic Archaea. Diet affects
not only the microbiota composition, but more signiﬁcantly the
metabolic activities of the microorganisms.
Obesity results from alterations in energy balance, that is,
how the body regulates energy intake, expenditure, and storage.
Because starvation poses a greater danger to an organism than
overabundance, our biological systems are geared to better pro-
tect against weight loss than weight gain (i.e., a thrifty genotype).
Considerable effort has been made to improve the availability and
stability of the food supply, resulting in an abundance of inexpen-
sive, palatable, and energy-dense foods. Consequently, humans
adapted for a situation of insufﬁciency are now confronted with
the easy availability of such foods. Recent evidence suggests that
the gut microbiota affect nutrient acquisition and energy regula-
tion and that obese and lean people have differences in their gut
microbial landscape. These ﬁndings raise the possibility that the
gut microbiota may have a role in the development of obesity (see
Figure 1; DiBaise et al., 2008; Cani and Delzenne, 2009).
In an elegant series of experiments, Backhed et al. (2004) found
that young conventionally reared mice have a 40% higher body fat
content than germ-free mice (gnotobiotic mice) even though they
consumed less food than their germ-free counterparts. The distal
gut microbiota from the normal mice were then transplanted into
the gnotobiotic mice (a process known as conventionalization),
resulting in a 60% increase in body fat within 2 weeks with-
out any increase in food consumption or obvious differences in
energy expenditure. The authors proposed that the gut micro-
biota promotes intestinal monosaccharides absorption, energy
extraction from non-digestible food components via SCFA pro-
duction through fermentation, de novo hepatic lipogenesis and
adipocyte fatty acid storage. The gut microbiota inﬂuence the
expression of host genes expressed in the intestine that control
fatty acid absorption, oxidation, and storage. One such target
is angiopoietin-related protein 4 (ANGPTL4), a potent lipopro-
tein lipase inhibitor. ANGPTL4 inhibits the uptake of fatty acids
from circulating triglyceride-rich lipoproteins in white adipose
and muscle tissues. Backhed et al. (2004) demonstrated that colo-
nizing germ-free mice with gut microbiota leads to a drop in the
intestinal expression of ANGPTL4. Several other proteins/systems
(such as the endocannabinoid system and the tight junction pro-
tein zona occludin-1) are inﬂuenced by gut colonization and are
changed upon dietary modulation of gut microbiota composition,
FIGURE 1 | Proposed mechanism whereby alteration of the bowel flora with a high-fat low-fiber diet alters the microbiota leading to metabolic
endotoxemia with increased lipid storage and decreased insulin sensitivity. Adapted with permission from Cani and Delzenne (2009).
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Table 1 | Major Bacteria and Archaea phyla and genera found in
the human gut microbiota. Reproduced with permission from

















which are implicated in the control of inﬂammation, gut barrier
function, gut motility, nutrient oxidation, and storage (Delzenne
and Cani, 2011).
Recent data suggests that SCFAs act not only as an energy sub-
strate for the host, but also as a signaling molecule. SCFAs act
as ligands for at least two G-protein-coupled receptors, GPR41
and GPR43 (Le Poul et al., 2003). Samuel et al. (2008) have
demonstrated that GPR41−/− mice colonized with a model of
fermentative microbial community did not gain fat mass at the
same extent as the wild-type littermates. On the basis that obe-
sity and insulin resistance is associated with low-grade chronic
systemic inﬂammation, Cani et al. (2007a) postulated another
mechanism linking the intestinal microbiota to the development
of obesity. They hypothesized that bacterial lipopolysaccharide
(LPS) derived from Gram-negative bacteria residing in the gut
microbiota acts as a triggering factor linking inﬂammation to a
high-fat diet-induced metabolic syndrome. In a series of exper-
iments in mice fed a high-fat diet they showed that a high-fat
diet increases endotoxemia, favors an increase in the Gram-
negative to Gram-positive colonizing bacteria and that chronic
endotoxemia induces obesity, insulin resistance, and diabetes (see
Figure 1; Cani et al., 2007a,b, 2009b). These authors demon-
strated that modulation of the intestinal microbiota by using
prebiotics in obese mice acts favorably on the intestinal bar-
rier, lowering the high-fat diet-induced LPS endotoxemia and
systemic and liver inﬂammation. Modulation of the gut ﬂora
with prebiotics has been demonstrated to increase glucagon-like
peptide-2 (GLP-2) production in the colon. Increased GLP-2
production is associated with higher expression of ZO-1 which
improves mucosal barrier function leading to a decrease of
plasma LPS.
To assess the relative abundance of various types of gut bac-
teria in obese and lean mice, Ley et al. (2005) analyzed bacterial
16S rRNA gene sequences from the cecal microbiota of geneti-
cally obese (ob/ob) mice, their lean ob/+ and +/+ siblings, and
their ob/+mothers, all fed the same polysaccharide-rich diet. They
found that the ob/ob mice had 50% fewer Bacteroidetes and corre-
spondingly more Firmicutes than their lean littermates, a ﬁnding
unrelated to differences in food consumption. Cani et al. (2007a,b)
demonstrated that induced obesity in rodents markedly reduced
the number of Biﬁdobacterium as well as Bacteroides-related bac-
teria. Ley et al. (2006) compared the distal gut microbiota of
obese and lean human subjects and found that obese people
had fewer Bacteroides and more Firmicutes than did lean con-
trol subjects. Interestingly, the authors observed that after weight
loss (following a fat restricted or a carbohydrate restricted low-
calorie diet), the ratio of Bacteroidetes to Firmicutes approached
a lean type proﬁle after 52 weeks of diet-induced weight loss
(Ley et al., 2006). Collado et al. (2008) observed signiﬁcant dif-
ferences in gut microbiota composition according to the body
weight during pregnancy. Interestingly, they found signiﬁcantly
higher numbers of Bacteroides group and of S. aureus in the
overweight state compared with normal-weight women, and they
established a positive correlation between the number of Bac-
teroides on the one hand, and the weight and BMI (before and
over pregnancy), on the other hand. The Biﬁdobacterium group
was present in higher numbers in normal weight than in over-
weight women and also in women with lower weight gain over
pregnancy. In addition, these researchers demonstrated that over-
weight mothers give birth to neonates that have a decreased
number of Biﬁdobacteria (Collado et al., 2010). The infants’ fecal
microbial composition was related to the weight and weight gain
of their mothers during pregnancy. This ﬁnding may be related to
the effect of colonization at birth and/or inheritable obesogenic
microbiota.
A recent paper has shown for the ﬁrst time in humans
that differences in the gut microbiota may precede overweight
development. Kalliomaki et al. (2008) have shown that Biﬁdobac-
terium spp. numberwas higher in childrenwho exhibited a normal
weight at 7 years than in children becoming overweight. They
observed that the Staphylococcus aureus was lower in children
who maintain a normal weight than in children becoming over-
weight several years later. The authors proposed that S. aureus
may act as a trigger of low-grade inﬂammation contributing to
the development of obesity.
Gastric-bypass surgery has been shown to be very effective
in reversing insulin resistance (Mingrone et al., 2012; Schauer
et al., 2012). This effect has been observed to occur early after
surgery and before the patients have had a signiﬁcant loss of
weight. It has been postulated that the surgically altered anatomy
and ﬂow of nutrients results in alteration of the microbiome
which may explain this ﬁnding (Cani and Delzenne, 2011).
Li et al. (2011) performed bacterial proﬁling to determine the
effect of Roux-en-Y gastric bypass in a non-obese rat model. At 2
weeks post-surgery they noted substantial shifts of the main gut
phyla toward higher concentrations of Proteobacteria (52-fold).
Lower concentrations of Firmicutes (4.5-fold) and Bacteroidetes
(twofold) in comparisonwith sham-operated rats were also found.
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EFFECT OF PREBIOTICS, PROBIOTICS, AND SYNBIOTICS
ON WEIGHT LOSS AND INSULIN RESISTANCE
The best non-surgical strategy for reversing obesity in the pop-
ulation may be to promote small but long-term changes in
diet and physical activity that take advantage of our biological
systems for regulating energy balance and preventing positive
energy balance. Although clearly no substitute for proper diet
and exercise, manipulation of the gut microbiota may represent
a novel approach for treating obesity, one that has few adverse
effects.
A probiotic is deﬁned as “a preparation of or a product con-
taining viable, deﬁned microorganisms in sufﬁcient numbers, which
alter the microﬂora of the host and by that exert beneﬁcial health
effects in this host” (Schrezenmeir and de Vrese, 2001). The term
prebiotic was introduced by Gibson and Roberfroid (1995), who
deﬁned prebiotics as “a non-digestible food ingredient that bene-
ﬁcially affects the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the colon.” The
term synbiotic is usedwhen a product contains both probiotics and
prebiotics.
PREBIOTICS
Prebiotic agents are non-digestible oligosaccharides that act as
“fertilizers” of the colonic microbiota, enhancing the growth
of beneﬁcial commensal organisms (e.g., Biﬁdobacterium and
Lactobacillus species; Schrezenmeir and de Vrese, 2001). Fructo-
oligosaccharides are prebiotic agents that are fermented by a
number of colonic bacteria to modulate the growth of beneﬁ-
cial bacteria (Roberfroid, 2002). The number of Biﬁdobacteria
has been shown to increase in the presence of inulin-type fruc-
tans with prebiotic properties. This increase occurs within a few
days, but rapidly disappears upon withdrawal of the prebiotic
compounds (after 1 week; Gibson and Roberfroid, 1995). The
extent of increase in the number of Biﬁdobacteria is also depen-
dent on their initial number in the gut. Breast-milk contains
oligosaccharides with prebiotic properties that contribute to the
increase in the number of Biﬁdobacteria after birth (Bode, 2009;
Chichlowski et al., 2011).
Dietary fructans, which are present in various fruits and
vegetables and added to food products, are used as an energy
substrate by bacteria, including Biﬁdobacterium spp., that express
β-fructofuranosidase, which promotes their development in the
gut. A remarkable increase has been observed in the number
of Biﬁdobacterium spp. in mice with diet-induced or geneti-
cally determined obesity that were supplemented with inulin-type
fructans (Cani et al., 2007b). Interestingly, the number of Biﬁ-
dobacteria was inversely correlated with the development of fat
mass, glucose intolerance, and LPS level (Cani et al., 2007b).
Inulin-type fructans increased the number of endocrine L cells
in the jejunum and in the colon of rodents, and promoted the
production and release of the active forms of GLP-1 and GLP-
2 in the portal vein (Cani et al., 2004). GLP-1 participates in
prebiotic-driven decreases in appetite, fat mass and hepatic insulin
resistance, whereas GLP-2, as mentioned before, contributes to
the reduced permeability of the intestinal wall and endotox-
emia that are associated with obesity (Cani et al., 2006, 2009b).
Interestingly, a 2-week treatment with inulin-type fructans
(16 g per day) in healthy volunteers increased the postprandial
release of gut peptides (namely GLP-1 and gastric inhibitory
peptide; Cani et al., 2009a).
Cani and colleagues demonstrated that in rats fed a standard
or high-fat diet, the addition of oligofructose to the diet reduced
energy intake and consumption and protected against weight gain
and fat-mass development, effects shown to be mediated by the
modulation of endogenous gut peptides involved in appetite and
weight regulation (Cani et al., 2004, 2005; Delzenne et al., 2005).
The authors also reported that oligofructose increased the gut
biﬁdobacterial content of high-fat diet-fed mice and that endotox-
emia signiﬁcantly and negatively correlated with Biﬁdobacterium
species (Cani et al., 2007b). Parnell and Reimer (2009) random-
ized 48 otherwise healthy adults with a BMI > 25 kg/m2 to receive
21 g oligofructose or a placebo (maltodextrin) for 12 weeks.
There was a reduction in body weight of 1.03 ± 0.43 kg with
oligofructose supplementation, whereas the control group expe-
rienced an increase in body weight of 0.45 ± 0.31 kg over 12
weeks (p = 0.01). A lower area under the curve (AUC) for ghrelin
(p= 0.004) and ahigherAUC for peptideYY (PYY)with oligofruc-
tose (p = 0.03) coincided with a reduction in self-reported caloric
intake (p < 0.05). Glucose decreased in the oligofructose group
and increased in the control group between initial and ﬁnal tests
(p < 0.05).
PROBIOTICS AND SYNBIOTICS
Probiotics have generated considerable interest in recent years
because studies investigating their use in a variety of clinical
conditions have yielded encouraging results (Floch and Mon-
trose, 2005). Probiotics have been demonstrated to be beneﬁcial
in necrotizing enterocolitis, in adults and children with infec-
tive diarrhea and for the prevention and treatment of antibiotic
associated diarrhea (Floch and Montrose, 2005; Hempel et al.,
2012). Probiotics belonging to a number of genera including
Lactobacillus, Biﬁdobacterium, Saccharomyces, Streptococcus, and
Enterococcus (Enterococcus faecium SF68) have been used in these
studies. The genus Lactobacillus comprises more than 90 species,
the most commonly used include L. acidophilus, L. rhamnosus,
L. casei, L. bulgaricus, L. plantarum, and L. reuteri. Most of the
clinical trials reported to date have used blends of various probi-
otic genera, primarily Lactobacillus spp. in combinationwith other
probiotics. The study of probiotics is complicated by the fact that
the efﬁcacy of these agents may be strain speciﬁc and the results
from one probiotic (or combination) cannot be extrapolated to
another. Furthermore, the results of clinical trials may depend on
the potency (concentration) and the measures used to ensure the
“bio-availability” of the bacteria. While probiotics are regarded
as safe, few prebiotics have received the FDA GRAS (Generally
Recognized as Safe) approval. Probiotics should be used with cau-
tion in critically ill and immunocompromised patients. In rare
cases, probiotics have been associated with serious adverse effects
in these patients including fungemia (Saccharomyces boulardii)
and bacterial sepsis (Riquelme et al., 2003; Land et al., 2005).While
clinical data supports the use of prebiotics and experimental data
supports the use of probiotics, few studies have investigated the
role of probiotics in patients with diabetes, insulin resistance,
and obesity.
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Luoto et al. (2010) randomized 159 women to receive Lacto-
bacillus rhamnosus GGor placebo 4weeks before expected delivery
with the intervention extending for 6 months postnatally. Anthro-
pometricmeasurements of the childrenwere followed for 10 years.
The perinatal probiotic intervention appeared to moderate the
initial phase of excessive weight gain (up to 48 months), espe-
cially among children who later became overweight. Kadooka
et al. (2010) conducted a multicenter, double-blind, randomized,
placebo-controlled intervention trial in which subjects (n = 87)
with an increased BMI (24.2–30.7 kg/m2) and abdominal visceral
fat area (81.2–178.5 cm2) were randomly assigned to receive either
fermented milk containing Lactobacillus gasseri SBT2055 (active
FM; n = 43) or fermented milk without LG2055 (control FM;
n = 44) for 12 weeks. Abdominal fat area was determined by com-
puted tomography. In the active FM group, abdominal visceral
and subcutaneous fat areas signiﬁcantly (p< 0.01) decreased from
baseline by an average of 4.6 and 3.3% respectively. Body weight
and other measures also decreased signiﬁcantly while, none of
these parameters changed signiﬁcantly in the control group.
Probiotics and synbiotics have been demonstrated to decrease
intestinal permeability and endotoxemia in patients with liver
disease and may serve as a model for reducing “metabolic endo-
toxemia” (Malaguarnera et al., 2010). In patients with minimal
hepatic encephalopathy, Liu et al. (2004) demonstrated that treat-
ment with a synbiotic signiﬁcantly increased the fecal content of
non-urease-producingLactobacillus species at the expense of other
bacterial species. Such modulation of the gut ﬂora was associated
with a signiﬁcant reduction in blood ammonia levels, reversal of
encephalopathy and a reduction in endotoxemia.
CONCLUSION
Experimental and clinical data demonstrate that obesity is asso-
ciated with changes in the intestinal microbiota. Furthermore,
provocative data suggest that manipulation of the microbiome
using prebiotics, probiotics, and synbiotics may reduce insulin
resistance and fat accumulation. While probiotics are regarded as
safe additional studies are required before such therapy can be
widely recommended.
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